FTY720: a new dimension in transplantation.
نویسنده
چکیده
IN CONTRAST TO the subfamily of neutrophil and mononuclear chemotactic cytokines (chemokines) upregulated by inflammation, FTY720 seems to affect the interactions of lymphocytes with the subfamily of homing chemokines, secondary lymphoid tissue chemokine (SLC) and essential myosin light chain chemokine (ELC). These homing chemokines are constitutively expressed in T-cell zones of secondary lymphoid structures (SLS), including peripheral lymph nodes (PLN), Peyer’s patches (PP), appendix, and spleen (SPL), wherein they attract lymphocytes and dendritic cells bearing the corresponding receptors CCR7 or CXCR3 (SLC) or only CCR7 (ELC). The chemokine receptor CCR7 is expressed on stomal elements within T-cell zones, on dendritic cells (DC), on B cells, on T lymphocytes bearing the Th1 as opposed to Th2 phenotype, and on memory cells remaining within SLS in contrast to the circulating effectors that generate inflammatory mediators. (CCR7 is not present on granulocytes or monocytes.) Following binding of CCR7 to ELC and SLC, lymphocytes display activation of integrin adhesion molecules, events necessary for incorporation into the critical microenvironment for immune maturation. Indeed, cells from CCR7 knockout (KO) mice fail to develop delayedtype hypersensitivity reactions or primary antibody responses.
منابع مشابه
FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.
Background-Effective immunosuppression is a critical determinant of organ and patient survival in cardiac transplantation. The present study was designed to determine the potency of FTY720, a new synthesized immunosuppressant, and examine its clinical potential as an immunosuppressant. Methods and Results-Hearts of DBA/2 mice were transplanted heterotopically in C57BL/6 mice. Recipients were tr...
متن کاملThe sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice.
OBJECTIVE The sphingosine-1-phosphate (S1P) analogue FTY720 is a potent immunosuppressive agent currently in Phase III clinical trials for kidney transplantation. FTY720 traps lymphocytes in secondary lymphoid organs thereby preventing their migration to inflammatory sites. Previously, we have identified FTY720 as a potent activator of eNOS. As both inhibition of immune responses and stimulatio...
متن کاملEarly administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation.
BACKGROUND Chronic rejection (CR) in terms of bronchiolitis obliterans (BO) and vascular sclerosis (VS) still represents the major obstacle for pulmonary graft survival in the medium and long term course after lung transplantation (LTX). Aside from nonspecific stimuli, early acute rejection (AR) seems to be causative especially in cases of a late diagnosis or inadequate treatment. This study in...
متن کاملFTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.
BACKGROUND FTY720 (fingolimod), a novel immunomodulator, has demonstrated potential for prevention of acute rejection in combination with cyclosporine. METHODS This study evaluated FTY720 2.5 mg versus mycophenolate mofetil (MMF) in a combination regimen with standard tacrolimus and corticosteroids in de novo renal transplant recipients for the composite efficacy within 6 months of transplant...
متن کاملPharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
FTY720 is a new and effective immunosuppressive agent, which produces peripheral blood lymphopenia through a lymphocyte homing effect. We investigated the relationship between the dose of FTY720 or blood concentration (pharmacokinetics, PK) and peripheral lymphopenia (pharmacodynamics, PD) in 23 kidney transplant recipients randomized to receive FTY720 (0.25-2.5 mg/day) or mofetil mycophenolate...
متن کاملThe impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients.
BACKGROUND FTY720 has recently demonstrated a similar efficacy in prevention of acute graft rejection compared with mycophenolate mofetil (MMF) in a large phase III trial of de novo renal transplant recipients. Creatinine clearance, however, was significantly lower in FTY720-treated patients. In the present study, we examined the impact of FTY720 on vascular function in a subgroup of patients o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Transplantation proceedings
دوره 33 7-8 شماره
صفحات -
تاریخ انتشار 2001